论文信息 - Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non–small-cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study.

Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non–small-cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study.

9520Background: Capmatinib (INC280) has shown promising efficacy in patients (pts) with MET exon 14 (METex14)–mutated NSCLC who were pretreated (cohort 4) or treatment (tx)-naive (cohort 5b) in the...